stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) EBITDA
Immunome, Inc.'s EBITDA for fiscal 2025 was −$224.0M, compared with −$306.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$268.3M. Over the past ten years it has ranged from −$306.6M (fiscal 2024) to −$7.2M (fiscal 2018); the current reading is higher than 25% of that period. Immunome, Inc. ranks 547th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$224.0M | — |
| FY2024 | −$306.6M | — |
| FY2023 | −$109.3M | — |
| FY2022 | −$36.3M | — |
| FY2021 | −$24.4M | — |
| FY2020 | −$11.5M | — |
| FY2019 | −$9.7M | — |
| FY2018 | −$7.2M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$77.4M | — |
| Mar 2026 | −$58.6M | — |
| Dec 2025 | −$72.1M | — |
| Sep 2025 | −$60.2M | — |
| 23 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| IMNM Immunome, Inc. | −$268.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$416.8M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. compare | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement